FGFR2 and cholangiocarcinoma: That study will investigate tinengotinib monotherapy in patients with cholangiocarcinoma with FGFR2 fusions for whom prior FGFR inhibitor therapy was unsuccessful, or those who responded to previous FGFR inhibitor(s), or with other FGFR alterations, or wild-type FGFR.